Department of Cardiothoracic Surgery, The Third Affiliated Hospital of Soochow University, Changzhou, 213003, China.
Comprehensive Laboratory, The Third Affiliated Hospital of Soochow University, Changzhou, 213003, China.
Pathol Res Pract. 2020 Apr;216(4):152849. doi: 10.1016/j.prp.2020.152849. Epub 2020 Feb 8.
The expression of cell surface receptors is abnormal in malignant tumors. The scavenger receptor class B type I (SR-B1) is an integral membrane glycoprotein receptor that facilitates the selective uptake of cholesterol by malignant cells. Accumulated studies investigated the prognostic role of SR-B1 in many solid tumors, such as breast cancer, lung cancer and so on. However, the conclusions remain undefined. Therefore, we conducted this meta-analysis to obtain more accurate evaluation of prognostic significance of SR-B1 in solid tumors.
We searched PubMed, Embase, Web of science and Cochrane library for eligible studies published before November 2018. The included studies investigated the association between the SR-B1 level and clinicopathological features including survival outcomes in solid tumors. Hazard ratios (HRs) with 95% confidence intervals (CIs) were adopted to assess the survival outcomes and odds ratio (ORs) with 95% confidence intervals (CIs) were pooled to evaluated the clinicopathological features.
A total of 10 studies involving 2585 patients were included in this meta-analysis. The results showed that low SR-B1 level was significantly correlated with earlier tumor grade (pooled OR = 2.09, 95%CI = 1.28-3.43, P = 0.001), less nodal involvement (pooled OR = 2.07, 95%CI = 1.43-3.0, P < 0.001), less distant metastasis (OR = 19.8, 95%CI = 2.58-151.65, P = 0.004), smaller tumor size (OR = 2.34, 95%CI = 1.53-3.57, P < 0.001), earlier TNM stage (OR = 3.77, 95%CI = 1.67-8.48, P = 0.001), lower recurrence (HR = 1.98, 95%CI = 1.57-2.49, P = 0.000), and better OS (HR = 1.99, 95%CI = 1.70-2.31, P = 0.000).
The low expression of SR-B1 was significantly associated with better clinicopathological status and longer survival in patients with solid tumors. SR-B1 might act as a promising prognostic biomarker for solid tumors.
细胞表面受体的表达在恶性肿瘤中异常。清道夫受体 B 类 I 型 (SR-B1) 是一种完整的膜糖蛋白受体，可促进恶性细胞选择性摄取胆固醇。大量研究调查了 SR-B1 在许多实体瘤中的预后作用，如乳腺癌、肺癌等。然而，结论仍不明确。因此，我们进行了这项荟萃分析，以获得对实体瘤中 SR-B1 预后意义的更准确评估。
我们检索了 PubMed、Embase、Web of Science 和 Cochrane 图书馆，以获取截至 2018 年 11 月发表的合格研究。纳入的研究调查了 SR-B1 水平与实体瘤中生存结局相关的临床病理特征之间的关系。采用风险比 (HR) 及其 95%置信区间 (CI) 评估生存结局，采用比值比 (OR) 及其 95%CI 评估临床病理特征。
共有 10 项纳入 2585 名患者的研究纳入本荟萃分析。结果表明，低 SR-B1 水平与肿瘤分级较早 (合并 OR = 2.09，95%CI = 1.28-3.43，P = 0.001)、淋巴结受累较少 (合并 OR = 2.07，95%CI = 1.43-3.0，P < 0.001)、远处转移较少 (OR = 19.8，95%CI = 2.58-151.65，P = 0.004)、肿瘤体积较小 (OR = 2.34，95%CI = 1.53-3.57，P < 0.001)、TNM 分期较早 (OR = 3.77，95%CI = 1.67-8.48，P = 0.001)、复发率较低 (HR = 1.98，95%CI = 1.57-2.49，P = 0.000)、OS 更好 (HR = 1.99，95%CI = 1.70-2.31，P = 0.000)。
SR-B1 低表达与实体瘤患者较好的临床病理状态和更长的生存时间显著相关。SR-B1 可能是一种有前途的实体瘤预后生物标志物。
